Pulmonary vasodilation in the rat by insulin in vitro could indicate potential hazard for inhaled insulin
- 26 July 2003
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 46 (9) , 1199-1202
- https://doi.org/10.1007/s00125-003-1172-y
Abstract
Hypoxic pulmonary vasoconstriction is an essential mechanism to prevent hypoxaemia in lung diseases. Insulin is known to be a systemic vasodilator but its effect on the pulmonary circulation is not known. Inhaled particulate insulin can generate locally high concentrations in the lung which could be physiologically important.Keywords
This publication has 7 references indexed in Scilit:
- TechnosphereTM/Insulin - proof of concept study with a new insulin formulation for pulmonary deliveryExperimental and Clinical Endocrinology & Diabetes, 2002
- Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept studyThe Lancet, 2001
- Time to Peak Insulin Level, Relative Bioavailability, and Effect of Site of Deposition of Nebulized Insulin in Patients with Noninsulin-Dependent Diabetes MellitusJournal of Aerosol Medicine, 1998
- Inhibition of hypoxic pulmonary vasoconstriction in isolated rat resistance arteries by atrial natriuretic peptideEuropean Respiratory Journal, 1997
- In vitro hypoxia on rat pulmonary artery: effects on contractions to spasmogens and role of KATP channelsEuropean Journal of Pharmacology, 1996
- Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary diseaseThe Lancet, 1996
- Insulin Across Respiratory Mucosae by Aerosol DeliveryDiabetes, 1971